A new series of 3-(methylthio)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives was synthesized. The structures of the new derivatives were confirmed by the spectral data and elemental analyses. The antitumor activity of this series against human breast adenocarcinoma cell line MCF7 was evaluated. Out of twenty new derivatives, ten were revealed mild to moderate activity compared with doxorubicin as a reference antitumor. Among this new series N-(2-chlorophenyl)-2-(3-(methylthio)-4-oxo-1-phenyl-1H-pyrazolo[3,4-d]py rimidin-5(4H)-yl)acetamide (13 a ) was found the most active one with IC 50 equal to 23 µM.
, Src kinase [10] , cyclin dependent kinase (CDK) [11] , mammalian target of rapamycin (mTOR) [12] and glycogen synthase kinase (GSK) [13] [14] . In addition, the presence of methyl sulphonyl group at the 3 position of pyrazolo [3,4-d] pyrimidine nucleus was reported to potentiate the antitumor activity of such nucleus [11] [15] . For example, compound 1 and 2 ( Figure 1 ) were exhibited excellent antitumor activity against breast adenocarcinoma cell line MCF7
with IC 50 values of 12.0 and 7.50 µM respectively [16] . Also, compound 3 displayed superior activity as cytotoxic against A549 cell line with IC 50 value of 5.28 µM [4] .
Based on these scientific facts and for further exploration of novel antitumor agents, we supposed that incorporation of these structural features together may result in potent antitumor agents that act on breast adenocarcinoma cell line. In this work, new 3-(methylthio)-1-phenyl-1H-pyrazolo [3,4-d] pyrimidine derivatives 10 -16 were synthesized, incorporating the methyl sulphonyl group at the 3 position of pyrazolo [3,4-d] pyrimidine ring system and varying the substituents at the 4 and 5 positions of such ring in order to study the effect of these varying substitutions on the antitumor activity of pyrazolo [3,4-d] pyrimidine nucleus against human breast adenocarcinoma cell line MCF7.
Results and Discussion

Chemistry
Scheme 1 shows the synthetic pathway of the starting pyrazolo [3,4-d] 4(5H)-one derivatives 8 and 4-chloro-3-(methylthio)-1-phenyl-1H-pyrazolo [3,4- d]pyrimidine (9) which were accomplished via reaction of malononitrile with carbon disulfide in the presence of sodium ethoxide followed by methylation of the product with dimethyl sulphate. The resulting 2 (bis(methylthio)methylene) malononitrile was then treated with phenyl hydrazine in absolute ethanol [17] .
Cyclization of the 5-amino-3-(methylthio)-1-phenyl-1Hpyrazole-4-carbonitrile 
Experimental
General
All melting points were taken on electro thermal (LA9000 SERIS) digital melting point apparatus and are uncorrected. IR spectra were recorded on PyeUnicam Sp 1000 spectrophotometer and were carried out at the Pharmaceutical Analytical Unit, Faculty of Pharmacy, Al-Azhar University, Egypt. The 1 HNMR and 13 CNMR spectra were recorded in DMSO-D 6 either on Varian Mercury VXR-300 NMR spectrophotometer at the Microanalytical Unit of Cairo University or BURKER 400 MHZ spectrophotometer at the Nuclear Magnetic Resonance Lab, Faculty of Pharmacy, Zagazig University, Egypt. Chemical shifts were related to that of the solvent. TMS was used a standard. Mass spectra were recorded on Hewlett Packard 5988 spectrometer at the Regional Center for Mycology & Biotechnology, Al-Azhar University, Cairo, Egypt. Progress of the reactions was monitored by TLC pre-coated with UV fluorescent silica gel and was visualized using UV lamp and different solvent systems as mobile phases. 5-Amino-3-(methylthio)-1-phenyl-1H-pyrazole-4-carbonitrile (7) and 3-(methylthio)-1-phenyl-1H-pyrazolo [3,4-d] pyrimidin-4(5H)-one (8) were prepared according to published method [17] . Compound 9 was obtained following reported Figure 2 . IC 50 in µM of the synthesized compounds and doxorubicin against MCF7 adenocarcinoma cell line.
procedure [19] . 2-Chloro-N-arylactamide and 3-chloro-N-arylpropanamide derivatives were prepared as reported [24] .
General Procedure for Synthesis of 3-(Methylthio)-1-Phenyl-N-Aryl-1H-Pyrazolo[3,4-d]Pyrimidin-4-Amines 10a-e
A mixture of compound 9 (10 mmol) and the appropriate aniline derivative (10 mmol) in absolute ethanol (35 ml) containing trimethylamine (15 mmol) was heated under reflux for 6 hours. The reaction mixture was cooled, and the separated solid was filtered, dried and finally recrystallized from ethanol. 
3-(Methylthio)-1-Phenyl-N-o-
General Procedure for Synthesis of 2-(3-(Methylthio)-4-Oxo-1-Phenyl-1H-Pyrazolo[3,4-d]Pyrimidin-5(4H)-yl)-NArylacetamide and N-Arylpropanamide 13a-h
Into a solution of compound 8 (10 mmol each) in DMF (30 ml) containing potassium carbonate (0.5 g), the appropriate 2-chloro N-arylacetamide or 3-chloro-N-arylpropanamide (10 mmol) was added. The reaction mixture was heated under reflux for 3 hours. After complete reaction, the reaction mixture was filtered while hot, concentrated, cooled and the resulting solid product was dried and finally recrystallized from ethanol. Into a solution of compound 9 (10 mmol) in DMF (30 ml) containing potassium carbonate (0.5 gm), the appropriate alkyl-2-chloroacetate (10 mmol) was added. The reaction mixture was heated under reflux for 4 hours. After complete reaction (as indicated by TLC), the reaction mixture was filtered while hot, concentrated, cooled and the resulting solid product was recrystallized from ethanol. 
2-(3-(Methylthio)-4-Oxo-1-Phenyl-1H-Pyrazolo[3,4-d]Pyrimidin-5(4H)-yl)-N-Phenylacetamide (13a)
N-(2-Chlorophenyl)-2-(3-(Methylthio)-4-Oxo-1-Phenyl-1H-
Pyrazolo[3,4-d]Pyrimidin-5(4H)-yl)Acetamide (13b)
2-(3-(Methylthio)-4-Oxo-1-Phenyl-1H-Pyrazolo[3,4-d]Pyrimidin-5(4H)-yl)-N-m-Tolylacetamide (13c)
Biological Testing
Materials and Method
Human breast adenocarcinoma cell line MCF7, were purchased from the American Type Cell Culture Collection (ATCC, Manassas, USA) and grown on Roswell Park Memorial Institute Medium (RPMI 1640) supplemented with 100 g/ml of streptomycin, 100 units/ml of penicillin and 10% of heat inactivated fetal bovine serum in a humidified, 5% (v/v) CO 2 atmosphere at 37˚C.
Measurement of Potential Antitumor
The antitumor activity of newly synthesized pyrazolo [3,4- Table 1 . 
Conclusion
